NCT03197298

Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome

Clopidogrel or Ticagrelor in Acute Coronary Syndrome Patients Treated With Newer-Generation Drug-Eluting Stents: CHANGE DAPT

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 2,062 (actual)
• Sponsor: Thorax Centrum Twente · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

Acute coronary syndrome (ACS) guidelines have been changed, favoring dual antiplatelet therapy (DAPT) with the more potent P2Y12 inhibitor ticagrelor over clopidogrel (besides aspirin). This change is based on studies that showed benefits of ticagrelor. However, study participants were only partly treated by percutaneous coronary intervention (PCI). In patients who were treated by PCI, this was generally performed using of bare metal or first-generation drug-eluting stents (DES). CHANGE DAPT is an investigator-initiated, prospective, single centre registry, in which we evaluate the impact of the guideline suggested change in the primary DAPT regimen (from clopidogrel to ticagrelor) on 1-year clinical outcome in ACS patients treated by PCI with newer-generation DES in the Thoraxcentrum Twente.

Conditions

• Acute Coronary Syndrome
• Percutaneous Coronary Intervention
• Drug-Eluting Stents

Interventions

Type	Name	Description
DRUG	Clopidogrel
DRUG	Ticagrelor

Timeline

• Start date: 2012-12-21
• Primary completion: 2016-07-25
• Completion: 2016-07-25
• First posted: 2017-06-23
• Last updated: 2017-06-23

Locations

1 site across 1 country: Netherlands